Home Cerveau Technologies Inc.

Cerveau Technologies Inc.

    Cerveau Technologies Inc. Signs Research Agreement with Takeda to Provide Novel Tau Imaging Agent

    The collaboration is focused on using [F-18]MK-6240 as a biomarker in Takeda’s neurodegenerative disease research. The companies will evaluate Takeda’s investigational therapeutics for potential treatment of neurodegenerative diseases in humans.

    RECENT COMMENTS